Dipexium Pharma (DPRX) Anticipates Announcing Data from Phase 3 Trials with Locilex Later This Month

October 20, 2016 7:28 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) today provided an update on the status of results from the two pivotal Phase 3 clinical trials (OneStep-1 and OneStep-2). Data tables and listings from both of these trials are currently being produced and evaluated by the Company's scientific advisors according to our pre-specified data review procedure.

David P. Luci, President and Chief Executive Officer of Dipexium stated, "We believe the process is nearing completion and anticipate announcing the data later this month after the scientific advisory team informs us of the unblinded results."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA, Management Comments

Add Your Comment